

Study to Evaluate Efficacy and Dose Response of Imapexptide (STEA-DI)

NCT07029412

Status	RECRUITING
Phase	Phase 2
Sponsor	MBX Biosciences
Enrollment	10 participants

Key Eligibility Criteria

Inclusion (6)

- Participant must be e18 to d75 years of age at the time of signing the informed consent.
 - Participants must have undergone RYGB or SG surgery at least 12 months prior to study entry.
 - Participants should have a documented history of PBH, defined as Whipple's triad (symptomatic hypoglycemia, capillary glucose d54 mg/dL, with symptom resolution by carbohydrate administration) and a minimum of 1 symptomatic hypoglycemic episode per month by patient report.
 - Participants who are either treatment naïve or who are no longer using (i.e., have discontinued as part of their usual medical care) agents known to interfere with glucose metabolism at the time of screening.
 - Participants must have a body mass index (BMI) \<45 kg/m2 at screening.
- ... and 1 more (see full listing online)

Exclusion (4)

- History of, or currently active, significant illness or medical disorders that in the opinion of the investigator may preclude participants from participating in the study.
- Currently on-going type II diabetes mellitus.
- History of hypoglycemia prior to bariatric surgery.
- History of insulinoma or other endogenous hyperinsulinemia illness (e.g., congenital hyperinsulinism).

Locations (4 total)

MBX Biosciences Investigational Site, Aurora, Colorado, United States
MBX Biosciences Investigational Site, Morehead City, North Carolina, United States
MBX Biosciences Investigational Site, Knoxville, Tennessee, United States
... and 1 more locations